公开(公告)号：EP3824891A1

公开(公告)日：2021-05-26

申请号：EP19837200.5

申请日：2019-07-18

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  Osaka University ,  Teikyo University

Inventor： AOSHI, Taiki ,  KOYAMA, Shohei ,  SUZUKI, Ryo

IPC: A61K31/7088 ,  A61K9/127 ,  A61K9/133 ,  A61K47/18 ,  A61K48/00 ,  A61P35/00 ,  A61P37/04

Abstract: An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.

公开(公告)号：EP3744829A1

公开(公告)日：2020-12-02

申请号：EP19740768.7

申请日：2019-01-17

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： PIAO, Zhenyu ,  KOIZUMI, Yuka ,  MIYATAKE, Hiroshi

IPC: C12N1/20 ,  C12Q1/02

Abstract: An object of the present invention is to provide a technique capable of further increasing the absolute detection value and/or the ratio of the detection value to a reference in a pneumococcal antibody sample evaluation test, or a technique capable of evaluating pneumococcal antibody samples against a wider variety of pneumococcal strains.
The object is achieved by a medium for preparing a pneumococcal sample for use in a pneumococcal antibody sample evaluation test, the medium containing a solid medium.

公开(公告)号：EP3037533A1

公开(公告)日：2016-06-29

申请号：EP14838190.8

申请日：2014-08-20

Applicant: Fujita Health University ,  The Research Foundation for Microbial Diseases of Osaka University ,  Perseus Proteomics Inc.

Inventor： KUROSAWA, Yoshikazu ,  OSHIMA, Nobuko ,  OKUNO, Yoshinobu ,  MITOMO, Katsuyuki ,  KOUDA, Katsushi

IPC: C12N15/09 ,  A61K39/395 ,  A61P31/16 ,  C07K16/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

CPC classification number: C07K16/1018 ,  C07K2317/76

Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).

Abstract translation: 本发明的目的是提供一种对流感病毒具有高结合活性和高中和活性的新型抗体。 本发明提供了中和H1流感病毒和/或H5流感病毒的抗体，其中该抗体具有重链可变区，其具有由定义的重链第一互补决定区（VH CDR1），定义重链 第二互补决定区（VH CDR2）和确定的重链第三互补决定区（VH CDR3）和轻链可变区，其具有由限定的轻链第二互补决定区（VL CDR2）和定义的 轻链第三互补决定区（VL CDR3）。

公开(公告)号：EP2471938A3

公开(公告)日：2013-04-24

申请号：EP12161534.8

申请日：2005-11-24

Applicant: The Research Foundation for Microbial Diseases of Osaka University ,  National Institute of Biomedical Innovation

Inventor： Mori, Yasuko ,  Somboonthum, Pranee ,  Yoshii, Hironori ,  Gomi, Yasuyuki ,  Takahashi, Michiaki ,  Yamanishi, Koichi

IPC: C12N15/869 ,  A61K39/165 ,  A61K39/25 ,  A61K39/295 ,  A61P31/22 ,  A61P37/04 ,  C12N5/00 ,  C12N7/00

CPC classification number: A61K39/25 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2710/16762 ,  C12N2760/18734 ,  C12N2800/204 ,  C12N2800/50 ,  C12N2820/55 ,  Y02A50/39 ,  Y02A50/394

Abstract: The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene.

公开(公告)号：EP2383343A3

公开(公告)日：2012-01-25

申请号：EP11153574.6

申请日：2005-03-03

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Nagaike, Kazuhiro ,  Mori, Yasuko ,  Gomi, Yasuyuki ,  Takahashi, Michiaki ,  Yamanishi, Kouichi

IPC: C12N15/38 ,  A61K39/25 ,  A61P31/22 ,  C12N5/10 ,  C12N7/00 ,  C07K14/04 ,  C12N7/04

CPC classification number: A61K39/25 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16761 ,  C12N2800/50 ,  C12N2820/55

Abstract: A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

公开(公告)号：EP2221368A1

公开(公告)日：2010-08-25

申请号：EP08846317.9

申请日：2008-11-07

Applicant: JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES ,  The Research Foundation for Microbial Diseases of Osaka University

Inventor： KOJIMA, Asato ,  TAKAHASHI, Hidehiro ,  ISHIKAWA, Toyokazu

IPC: C12N15/09 ,  A61K31/711 ,  A61K35/76 ,  A61K39/12 ,  A61P31/12 ,  C07K14/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02

CPC classification number: A61K39/12 ,  A61K31/711 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2770/24122 ,  C12N2770/24134 ,  Y02A50/394

Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the ALP secretion expression vector as an active ingredient.

Abstract translation: 本发明提供通过改变源自西尼罗病毒（WNV）的信号序列，信号肽，含有编码prM蛋白的核酸的WNV VLP分泌表达载体而获得的高度分泌或产生信号肽的病毒样颗粒（VLP），以及 E蛋白，含有载体的高分泌性或产生动物细胞系的WNP VLP，含有作为活性成分的细胞系获得的WNV VLP的WNV疫苗和含有ALP分泌表达载体作为活性成分的WNV DNA疫苗。

公开(公告)号：EP1057889B1

公开(公告)日：2009-04-22

申请号：EP99923858.7

申请日：1999-06-02

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： ISHIKAWA, Toyokazu, Kanonji Institute ,  YOSHII, Hironori, Kanonji Institute ,  ONISHI, Toshiyuki, Kanonji Institute ,  IMAGAWA, Tadashi, Kanonji Institute ,  ISHIBASHI, Masahide, Kanonji Institute

IPC: C12N7/06 ,  A61K39/12

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/70 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24163 ,  Y02A50/39

Abstract: The present invention provides a novel inactivated virus particle and a reinforced immunogen which have a reinforced titer about twice to about 10 times that of a conventional vaccine, as well as a method for producing the same. The inactivated virus particle of the present invention is useful in a diagnostic agent for infectious disease caused by a group of Japanese encephalitis viruses.

公开(公告)号：EP1932911A1

公开(公告)日：2008-06-18

申请号：EP06797474.1

申请日：2006-09-05

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： TAKEMOTO, Masaya ,  MORI, Yasuko ,  YAMANISHI, Koichi ,  FUKE, Isao ,  GOMI, Yasuyuki ,  TAKAHASHI, Michiaki

IPC: C12N15/09 ,  A01K67/027 ,  A61K39/00 ,  A61P7/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02

CPC classification number: C12N15/85 ,  A61K2039/53 ,  C12N2710/16522 ,  C12N2830/008 ,  C12N2830/60

Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.

Abstract translation: 旨在提供用于在免疫活性细胞和/或血细胞如淋巴细胞中选择性和强烈诱导表达的启动子。 在本发明中，目的是通过发现HHV6MIE启动子，HHV7MIE启动子和HHV7U95启动子在免疫活性细胞和/或血细胞如T淋巴细胞中意外诱导特异性表达来实现。 通过利用启动子，可以实现DNA疫苗的选择性递送等。

公开(公告)号：EP1721981A1

公开(公告)日：2006-11-15

申请号：EP05719956.4

申请日：2005-03-03

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： NAGAIKE, Kazuhiro ,  MORI, Yasuko ,  GOMI, Yasuyuki ,  TAKAHASHI, Michiaki ,  YAMANISHI, Kouichi

IPC: C12N15/38 ,  A61K39/25 ,  A61P31/22 ,  C12N5/10 ,  C12N7/00

CPC classification number: A61K39/25 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16761 ,  C12N2800/50 ,  C12N2820/55

Abstract: A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

Abstract translation: 重组水痘带状疱疹病毒; 其制造方法; 含有重组水痘带状疱疹病毒的药物组合物; 含有水痘带状疱疹病毒和BAC载体序列的基因组基因的载体; 含有上述载体的细胞; 能够与水痘带状疱疹病毒基因组同源重组的片段; 和含有BAC载体序列的核酸盒。 为此，提供了一种生产重组水痘带状疱疹病毒的方法，其包括使用BAC载体序列。

公开(公告)号：EP1074624B1

公开(公告)日：2005-04-13

申请号：EP99973716.6

申请日：1999-10-05

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： GOMI, Yasuyuki, Kanonji Institute ,  IMAGAWA, Tadashi, Kanonji Institute ,  OSAME, Juichiro, Kanonji Institute ,  TAKAHASHI, Toshiaki, Research Foundation ,  YAMANISHI, Koichi

IPC: C12N15/38 ,  C12N5/06 ,  C12N7/08 ,  C12P21/08 ,  C12Q1/68 ,  C12Q1/70 ,  C07K14/04 ,  C07K16/08 ,  A61K39/25 ,  A61K39/12

CPC classification number: C12Q1/705 ,  A61K2039/5254 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16722 ,  C12N2710/16761

Abstract: An attenuated chicken-pox virus Oka strain gene 62 having the base sequence represented by SEQ ID NO: 1 with at least the base substitutions (a) to (d) as specified below; (a) substitution of A at the 2110-position to G; (b) substitution of A at the 3100-position to G; (c) substitution of T at the 3818-position to G; and (d) substitution of A at the 4006-position to G; and a method for identifying the attenuated chicken-pox virus Oka strain and an attenuated chicken-pox virus strain acceptable as a virus strain for attenuated live chicken-pox vaccine.